Protagenic Therapeutics, Inc.\new Business Acquisition, Pro Forma Net Income (Loss)
Protagenic Therapeutics, Inc.\new (PTIX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$1.08 million for the 12-month period ending 2014-06-30, per its 10-K filed 2015-09-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2015-09-25
- Protagenic Therapeutics, Inc.\new business acquisition, pro forma net income (loss) for fiscal 2014 was -$1.08M.
- Protagenic Therapeutics, Inc.\new business acquisition, pro forma net income (loss) for fiscal 2013 was -$1.03M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2014-06-30 | -$1.08M 10-K · filed 2015-09-25 |
| 2013-06-30 | -$1.03M 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |